Drug development for neglected diseases: a deficient market and a public-health policy failure
Top Cited Papers
- 22 June 2002
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 359 (9324), 2188-2194
- https://doi.org/10.1016/s0140-6736(02)09096-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The AIDS Research ModelJAMA, 2001
- Risks in new drug development: Approval success rates for investigational drugsClinical Pharmacology & Therapeutics, 2001
- Drug Treatment of Tropical Parasitic InfectionsDrugs, 2000
- The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee EraDrug Information Journal, 2000
- Access to Essential Drugs in Poor CountriesA Lost Battle?JAMA, 1999
- Drug development output from 1975 to 1996: What proportion for tropical diseases?International Journal of Infectious Diseases, 1999
- Innovation deficit revisited: reflections on the productivity of pharmaceutical R&DDrug Discovery Today, 1998
- Orphan Drug Development—International Program and Study Design IssuesDrug Information Journal, 1998
- R&D Costs, Innovative Output and Firm Size in the Pharmaceutical IndustryInternational Journal of the Economics of Business, 1995
- Creating the Costliest Orphan:The Orphan Drug Act in the Development of Ceredase™International Journal of Technology Assessment in Health Care, 1992